These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35145479)

  • 1. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
    Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
    Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
    Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
    Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
    Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
    J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
    Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
    Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
    Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
    Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
    Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
    Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
    Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy.
    Oeverhaus M; Witteler T; Lax H; Esser J; Führer D; Eckstein A
    Horm Metab Res; 2017 Oct; 49(10):739-747. PubMed ID: 28922676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.
    Stan MN; Salvi M
    Eur J Endocrinol; 2017 Feb; 176(2):R101-R109. PubMed ID: 27760790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.